Mostrar el registro sencillo del ítem
dc.contributor.author | Salles, M.J.C. | |
dc.contributor.author | Zurita, J. | |
dc.contributor.author | Mejía, C. | |
dc.contributor.author | Villegas, M.V. | |
dc.contributor.author | Alvarez, C. | |
dc.contributor.author | Bavestrello, L. | |
dc.contributor.author | Berezin, E. | |
dc.contributor.author | Gotuzzo Herencia, José Eduardo | |
dc.contributor.author | Guzmán-Blanco, M. | |
dc.contributor.author | Labarca, J.A. | |
dc.contributor.author | Luna, C.M. | |
dc.contributor.author | Nouer, S. | |
dc.contributor.author | Rodríguez-Noriega, E. | |
dc.contributor.author | Seas Ramos, Carlos Rafael | |
dc.date.accessioned | 2022-01-04T20:29:57Z | |
dc.date.available | 2022-01-04T20:29:57Z | |
dc.date.issued | 2013 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12866/10449 | |
dc.description.abstract | Latin America has a high rate of community-associated infections caused by multidrug-resistant Enterobacteriaceae relative to other world regions. A review of the literature over the last 10 years indicates that urinary tract infections (UTIs) by Escherichia coli, and intra-abdominal infections (IAIs) by E. coli and Klebsiella pneumoniae, were characterized by high rates of resistance to trimethoprim/sulfamethoxazole, quinolones, and second-generation cephalosporins, and by low levels of resistance to aminoglycosides, nitrofurantoin, and fosfomycin. In addition, preliminary data indicate an increase in IAIs by Enterobacteriaceae producing extended-spectrum β-lactamases, with reduced susceptibilities to third- and fourth-generation cephalosporins. Primary-care physicians in Latin America should recognize the public health threat associated with UTIs and IAIs by resistant Gram-negative bacteria. As the number of therapeutic options become limited, we recommend that antimicrobial prescribing be guided by infection severity, established patient risk factors for multidrug-resistant infections, acquaintance with local antimicrobial susceptibility data, and culture collection. | en_US |
dc.language.iso | eng | |
dc.publisher | Cambridge University Press | |
dc.relation.ispartofseries | Epidemiology and Infection | |
dc.rights | info:eu-repo/semantics/restrictedAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
dc.subject | Latin America | en_US |
dc.subject | drug safety | en_US |
dc.subject | human | en_US |
dc.subject | prescription | en_US |
dc.subject | endemic disease | en_US |
dc.subject | geographic distribution | en_US |
dc.subject | risk factor | en_US |
dc.subject | disease surveillance | en_US |
dc.subject | disease association | en_US |
dc.subject | systematic review | en_US |
dc.subject | Drug resistance | en_US |
dc.subject | bacterial strain | en_US |
dc.subject | phenotype | en_US |
dc.subject | South and Central America | en_US |
dc.subject | genotype | en_US |
dc.subject | bacterium detection | en_US |
dc.subject | disease severity | en_US |
dc.subject | drug effect | en_US |
dc.subject | outpatient care | en_US |
dc.subject | drug efficacy | en_US |
dc.subject | treatment planning | en_US |
dc.subject | bacterial virulence | en_US |
dc.subject | antibiotic sensitivity | en_US |
dc.subject | amikacin | en_US |
dc.subject | clonal variation | en_US |
dc.subject | bacterium isolate | en_US |
dc.subject | Escherichia coli | en_US |
dc.subject | ciprofloxacin | en_US |
dc.subject | minimum inhibitory concentration | en_US |
dc.subject | quinoline derived antiinfective agent | en_US |
dc.subject | aminoglycoside | en_US |
dc.subject | ceftriaxone | en_US |
dc.subject | antibiotic resistance | en_US |
dc.subject | cefepime | en_US |
dc.subject | cefotaxime | en_US |
dc.subject | ceftazidime | en_US |
dc.subject | cephalosporin | en_US |
dc.subject | cotrimoxazole | en_US |
dc.subject | extended spectrum beta lactamase producing Enterobacteriaceae | en_US |
dc.subject | Klebsiella pneumoniae | en_US |
dc.subject | levofloxacin | en_US |
dc.subject | piperacillin plus tazobactam | en_US |
dc.subject | sultamicillin | en_US |
dc.subject | ampicillin | en_US |
dc.subject | meropenem | en_US |
dc.subject | urinary tract infection | en_US |
dc.subject | Salmonella | en_US |
dc.subject | abdominal infection | en_US |
dc.subject | amoxicillin plus clavulanic acid | en_US |
dc.subject | cefoxitin | en_US |
dc.subject | cephalosporin derivative | en_US |
dc.subject | Citrobacter | en_US |
dc.subject | concentration response | en_US |
dc.subject | Enterobacter | en_US |
dc.subject | ertapenem | en_US |
dc.subject | Escherichia coli infection | en_US |
dc.subject | extended spectrum beta lactamase producing Escherichia coli | en_US |
dc.subject | fosfomycin | en_US |
dc.subject | gentamicin | en_US |
dc.subject | Gram negative infection | en_US |
dc.subject | Gram-negative | en_US |
dc.subject | imipenem | en_US |
dc.subject | intra-abdominal infection | en_US |
dc.subject | Klebsiella pneumoniae infection | en_US |
dc.subject | nitrofurantoin | en_US |
dc.subject | outpatient | en_US |
dc.subject | Proteus | en_US |
dc.subject | Serratia | en_US |
dc.title | Resistant Gram-negative infections in the outpatient setting in Latin America | en_US |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | https://doi.org/10.1017/S095026881300191X | |
dc.subject.ocde | https://purl.org/pe-repo/ocde/ford#3.03.09 | |
dc.relation.issn | 1469-4409 |
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |